VIPR2
| VIPR2 | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| Wikidata | ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
Vasoactive intestinal peptide receptor 2 also known as VPAC2, is a
Tissue distribution
VIPR2 is
Function
adenylate cyclase activity.[9] Furthermore, VIPR2 mediates the anti-inflammatory effects of VIP.[10]
Research using VPAC2 knockout mice implicate it in the function of the circadian clock, growth, basal energy expenditure and male reproduction.[11][12][13][14]
VIPR2 and/or
cutaneous active vasodilation in humans.[15]
Splice variants may modify the immunoregulatory contributions of the VIP-VIPR2 axis.[16]
VIPR2 may contribute to autoregulation and/or coupling within the suprachiasmatic nucleus (SCN) core and to control of the SCN shell.[17]
Clinical significance
VIPR2 may play a role in schizophrenia.[18]
The abnormal expression of VIPR2
See also
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000106018 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000011171 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ a b "Entrez Gene: VIPR2 vasoactive intestinal peptide receptor 2". Archived from the original on 5 December 2010.
- S2CID 21204750.
- PMID 10850463.
- S2CID 9385702.
- ^ "IUPHAR-DB VPAC2 receptor Redirect". www.iuphar-db.org. Archived from the original on 3 March 2016. Retrieved 7 May 2018.
- PMID 18383383.
- S2CID 18583905.
- S2CID 2507786.
- PMID 15071099.
- PMID 12239111.
- PMID 20395540.
- PMID 16888203.
- S2CID 2389771.
- PMID 21285140.
- PMID 16552823.
Further reading
- Goetzl EJ, Pankhaniya RR, Gaufo GO, et al. (1998). "Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses". Ann. N. Y. Acad. Sci. 840 (1 NEUROIMMUNOMO): 540–50. S2CID 11871747.
- Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA (1995). "Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor". Biochem. Biophys. Res. Commun. 209 (2): 385–92. PMID 7733904.
- Svoboda M, Tastenoy M, Van Rampelbergh J, et al. (1995). "Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts". Biochem. Biophys. Res. Commun. 205 (3): 1617–24. PMID 7811244.
- Inagaki N, Yoshida H, Mizuta M, et al. (1994). "Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells". Proc. Natl. Acad. Sci. U.S.A. 91 (7): 2679–83. PMID 8146174.
- Xia M, Gaufo GO, Wang Q, et al. (1996). "Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors". J. Immunol. 157 (3): 1132–8. S2CID 40867208.
- Wei Y, Mojsov S (1997). "Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology". J. Neuroendocrinol. 8 (11): 811–7. S2CID 22302790.
- Mackay M, Fantes J, Scherer S, et al. (1997). "Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype". Genomics. 37 (3): 345–53. PMID 8938447.
- Nicole P, Du K, Couvineau A, Laburthe M (1998). "Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship". J. Pharmacol. Exp. Ther. 284 (2): 744–50. PMID 9454823.
- Dewit D, Gourlet P, Amraoui Z, et al. (1998). "The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes". Immunol. Lett. 60 (1): 57–60. PMID 9541464.
- Lutz EM, Shen S, Mackay M, et al. (1999). "Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2" (PDF). FEBS Lett. 458 (2): 197–203. S2CID 27842682.
- Busto R, Prieto JC, Bodega G, et al. (2000). "Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung". Peptides. 21 (2): 265–9. S2CID 44951090.
- Nicole P, Lins L, Rouyer-Fessard C, et al. (2000). "Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide". J. Biol. Chem. 275 (31): 24003–12. PMID 10801840.
- Bajo AM, Juarranz MG, Valenzuela P, et al. (2001). "Expression of vasoactive intestinal peptide (VIP) receptors in human uterus". Peptides. 21 (9): 1383–8. S2CID 429907.
- Lara-Marquez M, O'Dorisio M, O'Dorisio T, et al. (2001). "Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells". J. Immunol. 166 (4): 2522–30. PMID 11160313.
- Lara-Marquez ML, O'Dorisio MS, Karacay B (2001). "Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes". Ann. N. Y. Acad. Sci. 921 (1): 45–54. S2CID 8156918.
- Groneberg DA, Hartmann P, Dinh QT, Fischer A (2001). "Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways". Lab. Invest. 81 (5): 749–55. PMID 11351046.
- Juarranz MG, Bolaños O, Gutiérrez-Cañas I, et al. (2002). "Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors". Cell. Signal. 13 (12): 887–94. PMID 11728828.
- Fischer TC, Dinh QT, Peiser C, et al. (2002). "Simultaneous detection of receptor mRNA and ligand protein in human skin tissues". J. Cutan. Pathol. 29 (2): 65–71. S2CID 22886240.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. PMID 12477932.
External links
- "VIP and PACAP Receptors: VPAC2". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 3 March 2016. Retrieved 12 December 2008.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.